Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABSK 061

Next Previous
X
Search
Drug Profile

ABSK 061

Alternative Names: ABSK-061

Latest Information Update: 03 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 13 Nov 2024 Phase-II clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Combination therapy) in China (PO) (NCT06632262)
  • 09 Oct 2024 Abbisko Therapeutics plans a phase II trial for Solid tumours (Metastatic disease, Inoperable/Unresectable, Combination therapy) China (PO, Capsule) in November 2024 (NCT06632262)
  • 26 Feb 2024 Pharmacokinetics, adverse events and efficacy data from phase I trial in Solid tumours presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top